Scarica l'app Stockscreener
1.01
0.98%
-0.01
Precedente Chiudi:
$1.02
Aprire:
$1.04
Volume 24 ore:
912.56K
Relative Volume:
0.60
Capitalizzazione di mercato:
$170.15M
Reddito:
$8.95M
Utile/perdita netta:
$-21.49M
Rapporto P/E:
-8.4167
EPS:
-0.12
Flusso di cassa netto:
$-29.24M
1 W Prestazione:
+4.74%
1M Prestazione:
+48.97%
6M Prestazione:
+71.16%
1 anno Prestazione:
+9.96%
Intervallo 1D:
$0.993
$1.0599
Intervallo di 1 settimana:
$0.85
$1.09
Portata 52W:
$0.3651
$1.15
Lineage Cell Therapeutics Inc Stock (LCTX) Company Profile
Nome
Lineage Cell Therapeutics Inc
Settore
Industria
Telefono
510-871-4188
Indirizzo
2173 Salk Avenue, Suite 200, Carlsbad, CA
Confronta LCTX con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
LCTX
Lineage Cell Therapeutics Inc
|
1.01 | 170.15M | 8.95M | -21.49M | -29.24M | -0.12 |
|
VRTX
Vertex Pharmaceuticals Inc
|
459.62 | 115.95B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
547.36 | 56.52B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
331.91 | 39.44B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
543.48 | 35.14B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
245.49 | 28.51B | 3.81B | -644.79M | -669.77M | -6.24 |
Lineage Cell Therapeutics Inc Stock (LCTX) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2024-08-20 | Iniziato | Craig Hallum | Buy |
| 2022-11-02 | Iniziato | Robert W. Baird | Outperform |
| 2022-06-14 | Iniziato | B. Riley Securities | Buy |
| 2021-08-19 | Iniziato | Noble Capital Markets | Outperform |
| 2021-03-31 | Iniziato | Cantor Fitzgerald | Overweight |
Lineage Cell Therapeutics Inc Borsa (LCTX) Ultime notizie
Two Sigma Investments LP Buys New Shares in Lineage Cell Therapeutics, Inc. (NYSEAMERICAN:LCTX) - Defense World
Rising Demand in Allogeneic Stem Cells Market USD 2.0Bn By 2031 - openPR.com
Squarepoint Ops LLC Takes $46,000 Position in Lineage Cell Therapeutics, Inc. (NYSEAMERICAN:LCTX) - Defense World
Cell Therapy Manufacturing Market Exclusive Report with Detailed Study Analysis | WuXi AppTec, Healios Ltd. - newstrail.com
Lineage Cell Therapeutics appoints new auditor - Investing.com Australia
Two Sigma Advisers LP Has $44,000 Holdings in Lineage Cell Therapeutics, Inc. (NYSEAMERICAN:LCTX) - Defense World
Jane Street Group LLC Buys 142,965 Shares of Lineage Cell Therapeutics, Inc. (NYSEAMERICAN:LCTX) - Defense World
Lineage Cell Therapeutics Announces Updates to the 3rd Annual Spinal Cord Injury Investor Symposium - BioSpace
Deutsche Bank AG Has $87,000 Stock Position in Lineage Cell Therapeutics, Inc. (NYSEAMERICAN:LCTX) - Defense World
Future of Personalized Treatment: Stem Cell Therapy Market - openPR.com
B. Riley Predicts Lineage Cell Therapeutics FY2029 Earnings - Defense World
Transcript : Lineage Cell Therapeutics, Inc. Presents at H.C. Wainwright 3rd Annual BioConnect Investor Conference 2025, May-20-2025 02 - marketscreener.com
Spinal cord injury Pipeline 2025: Groundbreaking Clinical - openPR.com
Cell Therapy Manufacturing Market Is Booming Worldwide | WuXi - openPR.com
Lineage Cell Therapeutics Q2 EPS Lowered by HC Wainwright - Defense World
Lineage Cell Therapeutics outlines manufacturing milestone and anticipates OpRegen 36-month data update while advancing OPC1 clinical plans - MSN
Comerica Bank Boosts Position in Lineage Cell Therapeutics, Inc. (NYSEAMERICAN:LCTX) - Defense World
Lineage Cell Therapeutics’ Earnings Call Highlights Progress and Challenges - TipRanks
Barclays PLC Acquires 22,769 Shares of Lineage Cell Therapeutics, Inc. (NYSEAMERICAN:LCTX) - Defense World
Lineage to Present at 3rd Annual H.C. Wainwright BioConnect Inve - GuruFocus
Lineage Cell Therapeutics Q1 2025 Earnings: EPS Beats Estimates at -$0.02, Revenue Misses at $1.5 Million - GuruFocus
Lineage Cell Therapeutics, Inc. (AMEX:LCTX) Q1 2025 Earnings Call Transcript - Insider Monkey
Lineage to Present at 3rd Annual H.C. Wainwright BioConnect Investor Conference at Nasdaq NYC - Business Wire
Wells Fargo & Company MN Increases Stake in Lineage Cell Therapeutics, Inc. (NYSEAMERICAN:LCTX) - Defense World
Lineage Cell Therapeutics Inc (LCTX) Q1 2025 Earnings Call Highlights: Strategic Advances and ... - Yahoo Finance
Lineage Cell Therapeutics Inc (LCTX) Q1 2025 Earnings Call Highlights: Strategic Advances and Financial Resilience - GuruFocus
Lineage Cell Therapeutics Reports Q1 2025 Financials - TipRanks
Lineage Cell: Q1 Earnings Snapshot - Huron Daily Tribune
Lineage Cell Therapeutics earnings beat, revenue fell short of estimates By Investing.com - Investing.com Nigeria
Lineage Cell (LCTX) Reports Q1 Loss, Lags Revenue Estimates - Nasdaq
Lineage Cell Therapeutics Reports First Quarter 2025 Financial Results And Provides Business Update - marketscreener.com
Lineage Cell Therapeutics Reports First Quarter 2025 Financial Results and Provides Business Update - Business Wire
Examining the Future: Lineage Cell Therapeutics's Earnings Outlook - Nasdaq
RG6501 (OpRegen®) Phase 1/2a Clinical Study 36 Month Results to Be Featured at Clinical Trials at the Summit 2025 - Business Wire
Cell Therapy Manufacturing Market Projected To Witness Massive - openPR.com
Lineage Cell Therapeutics announces cGMP production success - Investing.com
Lineage Cell Therapeutics to Report First Quarter 2025 Financial Results and Provide Business Update on May 13, 2025 - BioSpace
Lineage Cell Therapeutics announces cGMP production success By Investing.com - Investing.com Nigeria
BlackRock, Inc.'s Strategic Acquisition of Lineage Cell Therapeu - GuruFocus
LCTX (Lineage Cell Therapeutics Inc) has impressive results - uspostnews.com
Lineage Cell Therapeutics (LCTX) to Release Earnings on Thursday - Defense World
JPMorgan Chase & Co. Raises Stock Holdings in Lineage Cell Therapeutics, Inc. (NYSEAMERICAN:LCTX) - Defense World
Upward Trajectory: Lineage Cell Therapeutics Inc (LCTX) Posts a Gaine, Closing at 0.47 - DWinneX
Lineage Cell Therapeutics, Inc. (NYSEAMERICAN:LCTX) Shares Bought by Renaissance Technologies LLC - Defense World
Lineage Cell Therapeutics Inc Inc. (LCTX) Price Performance: A Fundamental Analysis Perspective - investchronicle.com
Lineage Cell Therapeutics Inc [LCTX] Shares Rise 5.57 % on Thursday - knoxdaily.com
Stem Cell Therapy Market Growth, Trends, & Key Insights | Global - openPR.com
Lineage Cell Therapeutics Inc Azioni (LCTX) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
Lineage Cell Therapeutics Inc Azioni (LCTX) insider trading
| Commercio interno | Relazione | Data | Transazione | Costo | #Azioni | Valore ($) | #Azioni Totale |
|---|---|---|---|---|---|---|---|
| Howe Jill Ann | Chief Financial Officer |
Nov 26 '24 |
Buy |
0.59 |
15,000 |
8,850 |
25,500 |
| Samuel George A. III | General Counsel |
Nov 26 '24 |
Buy |
0.60 |
15,000 |
9,000 |
22,184 |
| Mulroy Michael H. | Director |
Nov 22 '24 |
Buy |
0.57 |
40,000 |
22,640 |
298,555 |
| Culley Brian M | President and CEO |
Nov 21 '24 |
Buy |
0.60 |
40,000 |
24,000 |
194,842 |
| Howe Jill Ann | Chief Financial Officer |
Aug 16 '24 |
Buy |
0.89 |
10,500 |
9,345 |
10,500 |
0.68%
0.50%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):